Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbinoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.93 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.93 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.93 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.93 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.93 |
| ▸ | LMNA | P02545 | 5/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.93 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.93 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.62 |
| ▸ | HRH2 | P25021 | 4/20 | 0.62 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.62 |
| ▸ | SCN1A | P35498 | 3/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbinoxamine SCHEMBL9095143 | 0.99 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Rotoxamine SCHEMBL141389 | 0.96 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Rotoxamine SCHEMBL29485023 | 0.96 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Carbinoxamine SCHEMBL5070 | 0.96 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Carbinoxamine SCHEMBL29881788 | 0.96 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Carbinoxamine SCHEMBL29414093 | 0.96 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Carbinoxamine SCHEMBL8709373 | 0.95 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Carbinoxamine SCHEMBL4074917 | 0.94 | CHRM2 (0.83) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| Carbinoxamine SCHEMBL6626762 | 0.94 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B | |
| SCHEMBL29730949 | 0.91 | CHRM2 (0.80) | CHRM2SLC6A2SLC6A4SLC6A3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192218-A1 | REGENERATIVE HELMINTH CONTAINING COMPOSITIONS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20180207206-A1 | TREATMENT TO PROMOTE WOUND HEALING | UNIV RUTGERS (US) | 2018-07-26 | — | — | US | disclosed |
| US-9931361-B2 | Treatment to promote wound healing | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3000472-B1 | COMPOSITIONS FOR PREVENTING ATRIAL AND VENTRICULAR FIBRILLATION | CORMATRIX CARDIOVASCULAR INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9446078-B2 | Sterilized and decellularized extracellular matrix for treating cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9308225-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-3000472-A1 | COMPOSITIONS FOR PREVENTING ATRIAL AND VENTRICULAR FIBRILLATION | Cormatrix Cardiovascular, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2398502-B1 | COMPOSITIONS AND METHODS FOR PREVENTING CARDIAC ARRHYTHMIA | CORMATRIX CARDIOVASCULAR INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9119841-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9089549-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8916515-B2 | Compositions and methods for promoting wound healing and tissue regeneration | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-12-23 | — | — | US | disclosed |
| US-8877224-B2 | Compositions for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130316013-A1 | Compositions for Preventing Cardiac Arrhythmia | CORVIVO CARDIOVASCULAR, INC. | 2013-11-28 | — | — | US | disclosed |
| US-20130274206-A1 | Compositions and Methods for Promoting Wound Healing and Tissue Regeneration | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012166539-A1 | COMPOSITIONS FOR PREVENTING CARDIAC ARRHYTHMIA | CORMATRIX CARDIOVASCULAR, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120251507-A1 | COMPOSITIONS FOR PREVENTING CARDIAC ARRHYTHMIA | CORMATRIX CARDIOVASCULAR, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120219568-A1 | EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER | ZHEJIANG UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20120046329-A1 | MODULATORS OF NOD1 AND NOD2 SIGNALING, METHODS OF IDENTIFYING MODULATORS OF NOD1 AND NOD2 SIGNALING, AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-02-23 | — | — | US | disclosed |
| US-20100233235-A1 | COMPOSITIONS AND METHODS FOR PREVENTING CARDIAC ARRHYTHMIA | CORVIVO CARDIOVASCULAR, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100120679-A1 | Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy | SOUTHERN RESEARCH INSTITUTE (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120679-A1 | Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy | ATM, MRE11, DCLRE1A | HRH1 3629/4885CHRM2 4838/4885SLC6A2 4392/4885 |
| US-20120219568-A1 | EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER | TOP2A, EI24, BAD | HRH1 2916/4885CHRM2 4425/4885SLC6A2 3734/4885 |
| US-20130274206-A1 | Compositions and Methods for Promoting Wound Healing and Tissue Regeneration | MMP8, MMP1, COL2A1 | HRH1 4177/4885CHRM2 4604/4885SLC6A2 4687/4885 |
| US-20120046329-A1 | MODULATORS OF NOD1 AND NOD2 SIGNALING, METHODS OF IDENTIFYING MODULATORS OF NOD1 AND NOD2 SIGNALING, AND USES THEREOF | NOD2, NOD1, NLRP1 | HRH1 618/4885CHRM2 2101/4885SLC6A2 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.